Drug Approval | November 16, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
This collaboration turns kitting into a strategic advantage for sponsors and sites
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Diversifying its portfolio to include late-phase antiviral agent
The observations are procedural in nature and will be responded to within the stipulated time
Subscribe To Our Newsletter & Stay Updated
